Tech Company Financing Transactions
Remedy Plan Therapeutics Funding Round
Remedy Plan Therapeutics closed a $18 million financing round on 5/13/2025. Backers included Alexandria Venture Investments, Schooner Capital and private investors.
Transaction Overview
Company Name
Announced On
5/13/2025
Transaction Type
Amount
$18,000,000
Round
Undisclosed
Proceeds Purpose
The company intends to use the funds to accelerates advancement of RPT1G, a novel NAMPT inhibitor, into a Phase 1/2 trial in patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS)
Company Information
Company Status
Private & Independent
Industry
Healthcare Services
Mailing Address
Undisclosed
Gaithersburg, MD Undisclosed
USA
Gaithersburg, MD Undisclosed
USA
Phone
Undisclosed
Website
Email Address
Overview
All human cells require energy (e.g., sugar and fat) to function and survive, and the NAMPT enzyme controls how cells use energy. Well-regulated NAMPT activity is paramount to human health, with thousands of research articles connecting NAMPT dysregulation to more than 20 distinct diseases, spanning oncology, autoimmune and metabolic disorders. To treat these numerous diseases, many Pharma companies tried to make NAMPT-targeting drugs; however, they all caused significant on-target toxicity and none have advanced beyond Phase 2 clinical trials.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Greg Crimmins
Browse more venture capital transactions:
Prev: 5/13/2025: Complement 1 venture capital transaction
Next: 5/13/2025: FlexPoint venture capital transaction
Share this article
News on VC Transactions
We do our best to report on every notable VC transaction. All VC database entries on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs